OncoSec Medical Incorporated (OTCQB: ONCS) saw its share volume slightly drop on May 15th with 2,589,613 shares exchanging hands, relatively lower than its three month daily average volume of 3,420,852 shares.
This comes after OncoSec Medical Inc., a company developing its ImmunoPulse DNA-based immunotherapy to treat solid tumors, announced that it will be a featured presenter at the 3rd Annual Marcum MicroCap Conference on Thursday, May 29, 2014 in New York City at the Grand Hyatt Hotel.
The annual Marcum MicroCap Conference is a signature showcase for superior quality, under-followed public companies with less than $500 million in market capitalization.
ONCS closed at $.752 on May 15th, up 1.62% from its previous close of $.74.
PennyPickAlerts.com is one of the most talked about stock newsletters in the world. To receive 100% FREE stock alerts that have incredible potential, sign up here:
InVivo Announces Second Clinical Site For Its Clinical Study
InVivo Therapeutics Holdings Corp. (OTCQB: NVIV) saw its share volume remain strong on May 15th with 341,307 shares exchanging hands, slightly higher than its three month average daily volume of 302,210 sharesl
This uptick in volume comes after InVivo Therapeutics Holdings Corp. announced that a second clinical site in its clinical study, the Carolinas Medical Center in Charlotte, NC, is now open for enrollment for patients with acute spinal cord injury (SCI). Dom Coric, MD, of Carolina Neurosurgery & Spine Associates, Chief of Neurosurgery at Carolinas Medical Center, is a Co-Principal Investigator. William L. Bockenek, MD, Chief Medical Officer of Carolinas Rehabilitation, part of the Carolinas HealthCare System, and Chairman of the Department of Physical Medicine and Rehabilitation at Carolinas Medical Center, is also a Co-Principal Investigator.
This is the company’s first clinical study of its degradable polymer Neuro-Spinal Scaffold. The pilot study has been approved by the U.S. Food and Drug Administration (FDA) and is intended to capture preliminary safety and effectiveness data of the Neuro-Spinal Scaffold in up to five human subjects with acute thoracic spinal cord injury. The company then expects to conduct a pivotal study to obtain FDA approval to commence commercialization under a Humanitarian Device Exemption (HDE). In commenting about the significance of this study, Dr. Coric said: “We are excited to initiate the study of this innovative surgical treatment for neurologically devastating spinal cord injury at the Carolinas Medical Center.”
NVIV closed at $1.20 on May 15th, up one cent from its previous close of $1.19.
Generex Biotechnology Corp. Sees Its Volume Skyrocket
Generex Biotechnology Corp. (OTCQB: GNBT) saw its share volume soar on May 15th with 9,706,848 shares exchanging hands, three times higher than its three month daily average volume of 3,446,516 shares.
With no new news, let’s focus on what the company does:
Generex is engaged in the research, development, and commercialization of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist™ device. Antigen Express, Inc. is a wholly owned subsidiary of Generex. The core platform technologies of Antigen Express comprise immunotherapeutic vaccines for the treatment of malignant, infectious, allergic, and autoimmune diseases. Antigen Express has pioneered the use of specific CD4+ T-helper stimulation technologies in immunotherapy. One focuses on modification of peptides with Ii-Key to increase potency, while a second relies on inhibition of expression of the Ii protein. Antigen Express scientists, and others, have shown clearly that suppression of expression of the Ii protein in cancer cells allows for potent stimulation of T-helper cells and prevents the further growth of cancer cells.
GNBT closed at $.0293 on May 15th, 10.94% lower than its previous close of $.0329.
Nuvilex Signs Research Agreement With The University Of Northern Colorado
Nuvilex, Inc. (OTCQB: NVLX) saw its share volume plummet on May 15th with 1,674,223 shares exchanging hands, significantly lower than its three month daily average volume of 11,386,248 shares.
Just last week, Nuvilex, Inc., a clinical-stage international biotechnology company providing cell and gene therapy solutions for the treatment of diseases, announced that it has signed a Research Agreement with the University of Northern Colorado to perform initial studies in the development of cancer treatments that combine the proprietary live-cell encapsulation technology known as Cell-in-a-Box(R) with constituents of Cannabis known as cannabinoids. Richard M. Hyslop, Ph.D., Professor of Chemistry and Biochemistry at the University of Northern Colorado and member of the Scientific Advisory Board at Medical Marijuana Sciences, a wholly owned subsidiary of Nuvilex, will lead the efforts.
"Dr. Hyslop and his team at the University of Northern Colorado will seek to establish a solid foundation for future preclinical studies and clinical trials that will be needed as Medical Marijuana Sciences develops treatments for serious and deadly diseases such as brain and pancreatic cancers," said Kenneth L. Waggoner, CEO and president of Nuvilex. "The goal is to develop a Cell-in-a-Box(R) /cannabinoid combination that has anticancer effects coupled with low toxicity similar in concept to Nuvilex's pancreatic cancer treatment currently being prepared for Phase 2b clinical trials that uses the Cell-in-a-Box(R) technology with low doses of the chemotherapeutic drug ifosfamide."
NVLX closed at $.3165 on May 15th.
Pennypickalerts.com issues momentum alerts on stocks that can provide gains to day traders.
Pennypickalerts.com provides members with timely information and exclusive alerts on cheap and under-valued stocks in the United States with the potential to deliver gains of 100% - 200% or more.
Pennypickalerts.com monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities. Through a vast network of IR professionals Pennypickalerts.com is often in the know of several large investor awareness campaigns being deployed.
Timing is everything when trading Penny Stocks. Gain an Edge by joining the Pennypickalerts.com newsletter and receiving alerts from a Pro-Active team of researchers. Pennypickalerts.com believes traders should have a chance at successfully trading penny stocks and invites traders and investors to be part of the Free VIP membership.
Simply sign up for free and start receiving exclusive alerts.
Subscribe Here: http://www.pennypickalerts.com
Pennypickalerts.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always own due diligence with any potential investment.